Trials
Search / Trial NCT05637242

Ventricular Assist Device (VAD) Research Registry and Blood Sub-Study

Launched by SPECTRUM HEALTH HOSPITALS · Nov 23, 2022

Trial Information

Current as of February 05, 2025

Terminated

Keywords

Ventricular Assist Device

ClinConnect Summary

Patients eligible for VAD are being sampled before surgery for plasma as well as peripheral blood cells. After surgery patients are being sampled again at 24 h and 7 days. Inflammatory response is being monitored on gene expression as well as cell level and on cytokine level in relation to the outcome.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Subject is ≥ 18 years of age
  • 2. Subject is treated with a VAD at the Butterworth Campus, Spectrum Health.
  • Exclusion Criteria:
  • 1. Subject is less than 18 years of age.
  • 2. Known prisoners of the state.
  • 3. Subject is pregnant.
  • 4. Non- English speaking patients will be excluded from the blood sub-study

Trial Officials

Renzo Loyaga, MD PhD

Principal Investigator

The DeVos Cardiovascular Research Program, Frederik Meijer Heart & Vascular Institute, Corewell Health

About Spectrum Health Hospitals

Spectrum Health Hospitals is a leading healthcare provider dedicated to delivering high-quality patient care and advancing medical research through innovative clinical trials. As a part of a comprehensive health system, Spectrum Health Hospitals integrates cutting-edge technology and evidence-based practices to enhance patient outcomes and contribute to the broader medical community. With a commitment to ethical standards and patient safety, Spectrum Health Hospitals actively engages in diverse clinical research initiatives, fostering collaboration among healthcare professionals, researchers, and participants to drive advancements in treatment and therapeutic options.

Locations

Grand Rapids, Michigan, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials